Press releases
2023
10 November, 2023
Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan
8 November, 2023
Interim report Q3 2023
1 November, 2023
Egetis’ Nomination Committee for the 2024 Annual General Meeting
31 October, 2023
Change in the number of shares and votes in Egetis Therapeutics
11 October, 2023
Egetis Therapeutics publishes prospectus for admission to trading of shares, in the private placement, on Nasdaq Stockholm
22 August, 2023
Interim report Q2 2023
28 June, 2023
Egetis announces site activation in the pivotal ReTRIACt trial for Emcitate® and updates timeline for the US NDA submission
26 April, 2023
Interim report January-March 2023
30 March, 2023
Egetis comments on market rumors
28 March, 2023
Egetis Therapeutics’ 2022 annual report published
22 February, 2023
Year-end Report Q4 2022
31 January, 2023
Change in the number of shares and votes in Egetis Therapeutics
25 January, 2023
Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 210 million
24 January, 2023
Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 200 million
2022
8 November, 2022
Interim report January-September 2022
19 August, 2022
Interim report Q2 2022